Direxion Daily S&P Biotech Bull 3X ETF (LABU) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 3.85: the stock has moved about 285% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerDirexion Daily S&P Biotech Bull 3X ETF (LABU) trades at $248.72. Direxion Daily S&P Biotech Bull 3X ETF (LABU) aims for 300% of the daily performance of the S&P Biotechnology Select Industry Index. Sector: Financials.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for LABU: LABU does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
Direxion Daily S&P Biotech Bull 3X ETF (LABU) Financial Services Profile
Direxion Daily S&P Biotech Bull 3X ETF (LABU) is a leveraged ETF seeking to magnify the daily returns of the S&P Biotechnology Select Industry Index by 300%, targeting short-term traders who aim to capitalize on the biotechnology sector's daily movements, but face risks from compounding.
What Is the Investment Thesis for LABU?
LABU offers a high-risk, high-reward proposition for short-term traders who believe the biotechnology sector will experience significant positive momentum on a given day. With a beta of 3.85, LABU is significantly more volatile than the broader market. The primary value driver is the fund's ability to deliver 3x the daily performance of its underlying index. However, the effects of compounding can erode returns over longer periods, especially in volatile markets. The fund's success hinges on accurately predicting short-term movements in the biotechnology sector. Investors should closely monitor the S&P Biotechnology Select Industry Index and be aware of the risks associated with leveraged ETFs before investing in LABU.
Based on FMP financials and quantitative analysis
LABU Key Highlights
LABU seeks daily investment results of 300% of the performance of the S&P Biotechnology Select Industry Index.
- The fund is designed for short-term trading and is not suitable for long-term investment due to the effects of compounding.
- LABU utilizes financial instruments such as swaps and futures contracts to achieve its leveraged exposure.
- The fund's market capitalization is $0.79 billion.
- LABU has a beta of 3.85, indicating significantly higher volatility than the market.
Who Are LABU's Competitors?
LABU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BUFF Innovator Laddered Allocation Power Buffer ETF | $54.11 | +0.32% | $898M | — |
| DPST Direxion Daily Regional Banks Bull 3X ETF | $115.81 | +3.35% | $883M | — |
| EMCS Xtrackers MSCI Emerging Markets Climate Selection ETF | $47.28 | +1.02% | $1.09B | — |
| IVES Dan Ives Wedbush AI Revolution ETF | $41.84 | +1.01% | $1000M | — |
| KIE State Street SPDR S&P Insurance ETF | $59.24 | +0.05% | $419M | — |
| BLK BlackRock, Inc. | $1059.63 | -0.44% | $164B | — |
| BX Blackstone Inc. | $111.74 | -0.45% | $135B | — |
| APOS Apollo Global Management, Inc. | $25.59 | -0.23% | $74.8B | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LABU's Key Strengths?
Offers high potential returns for short-term traders.
- Provides leveraged exposure to the biotechnology sector.
- Liquid and easily tradable on major exchanges.
What Are LABU's Weaknesses?
High risk due to leverage and daily rebalancing.
- Susceptible to erosion of value due to compounding, especially in volatile markets.
- Not suitable for long-term investment.
What Are the Key Risks for LABU?
Negative clinical trial results for major biotechnology companies.
- Regulatory setbacks or delays in drug approvals.
- High volatility in the biotechnology sector.
- Effects of compounding eroding returns over longer periods.
- Changes in interest rates affecting the valuation of biotechnology companies.
What Threats Does LABU Face?
- Regulatory changes affecting leveraged ETFs.
- Increased competition from other leveraged and inverse products.
- Market downturns in the biotechnology sector.
What Are LABU's Competitive Advantages?
- Established brand recognition as a provider of leveraged and inverse ETFs.
- Proprietary strategies for managing and rebalancing leveraged ETF portfolios.
- First-mover advantage in offering a 3x leveraged ETF focused on the biotechnology sector.
What Does LABU Do?
The Direxion Daily S&P Biotech Bull 3X ETF (LABU) is designed to provide traders with a leveraged exposure to the biotechnology sector. Launched with the objective of delivering three times the daily performance of the S&P Biotechnology Select Industry Index, LABU caters to investors seeking to amplify their returns on a short-term basis. The fund achieves this through the use of financial instruments such as swaps, futures contracts, and other derivatives. LABU is not intended for long-term investment strategies. Its structure is tailored for sophisticated investors who understand the risks associated with leveraged ETFs, including the potential for amplified losses and the effects of compounding, which can cause the fund's performance to diverge significantly from the underlying index over longer periods. The fund's daily rebalancing aims to maintain the 3x leverage, but this also contributes to the potential for volatility and erosion of value, particularly in choppy or sideways-moving markets. LABU is part of Direxion's suite of leveraged and inverse ETFs, which cover a wide range of sectors and asset classes, offering traders tools to express their short-term market views.
What Products and Services Does LABU Offer?
- Provides 3x leveraged exposure to the daily performance of the S&P Biotechnology Select Industry Index.
- Offers a tool for short-term traders to amplify their returns in the biotech sector.
- Utilizes financial instruments such as swaps and futures contracts to achieve its leverage.
- Rebalances its portfolio daily to maintain the 3x leverage ratio.
- Trades on major exchanges, providing liquidity for investors.
- Offers an alternative to trading individual biotech stocks with leverage.
How Does LABU Make Money?
- Generates revenue through management fees charged on the fund's assets under management (AUM).
- Aims to provide 3x the daily return of the S&P Biotechnology Select Industry Index, attracting traders seeking leveraged exposure.
- Utilizes derivatives and other financial instruments to achieve its investment objective.
What Industry Does LABU Operate In?
LABU operates within the asset management industry, specifically focusing on leveraged ETFs. The ETF market has seen substantial growth in recent years, with investors increasingly using these products to express tactical views and manage risk. Leveraged ETFs like LABU offer the potential for amplified returns but also come with increased risk. The biotechnology sector, which LABU tracks, is characterized by high growth potential and significant volatility, driven by factors such as drug approvals, clinical trial results, and regulatory changes. The competitive landscape includes other leveraged ETFs and traditional biotechnology funds, each with varying risk and return profiles.
Who Are LABU's Key Customers?
- Short-term traders seeking to capitalize on daily movements in the biotechnology sector.
- Sophisticated investors who understand the risks associated with leveraged ETFs.
- Hedge funds and other institutional investors using LABU for tactical trading strategies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an etf, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 41 snapshots
| 2026-08-23 | 42 |
| 2026-08-31 | 42 |
| 2026-09-08 | 42 |
| 2026-09-16 | 42 |
| 2026-09-24 | 42 |
| 2026-10-04 | 42 |
What changed?
The score has stayed at 42.
Over the same 30 days the stock moved -18.1%.
LABU Financials
Bull Case vs Bear Case
Bull Case
- Offers high potential returns for short-term traders.
- Provides leveraged exposure to the biotechnology sector.
- Liquid and easily tradable on major exchanges.
- Upcoming: Positive clinical trial results for major biotechnology companies in the S&P Biotechnology Select Industry Index.
Bear Case
- High risk due to leverage and daily rebalancing.
- Susceptible to erosion of value due to compounding, especially in volatile markets.
- Not suitable for long-term investment.
- Potential: Negative clinical trial results for major biotechnology companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
LABU Latest News
No recent news available for LABU.
LABU Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LABU.
Price Targets
Wall Street price target analysis for LABU.
LABU MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LABU; grades run from A+ (80-100) to F (below 30).
Common Questions About LABU (Financials)
What are the main risks for LABU?
The primary risks associated with LABU stem from its leveraged structure and daily rebalancing. The 3x leverage amplifies both gains and losses, making it highly sensitive to market volatility. The effects of compounding can erode returns over time, especially in choppy or sideways-moving markets.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- The information provided is based on available data and is intended for informational purposes only.
- Investors should conduct their own research and consult with a financial advisor before making any investment decisions.